Skip to main content
SpringerLink
Log in

Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer

  • Chapter
Book cover Ovarian Cancer 3

  • 96 Accesses

Abstract

Taxol was identified 22 years ago as the active substance of the bark of the Pacific yew, Taxus brevifolia [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wani, M.C., Taylor, H.L., Wall, M.E. et al (1971) Plant antitumor agents. VL The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325–7.

    Article  CAS  Google Scholar 

  2. Schiff, P.B., Fant, J. and Horwitz, S.B. (1979) Promotion of microtubule assembly in vitro by Taxol. Nature 22, 665–7.

    Article  Google Scholar 

  3. Schiff, P.B. and Horwitz, S.B. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77,1561–5.

    Article  PubMed  CAS  Google Scholar 

  4. Rowinsky, E.K., Cazenave, L.A. and Donehower, R.C. (1990) Taxol: a novel investigational antimicrotubule agent. J. Natl Cancer Inst., 1247–59.

    Google Scholar 

  5. McGuire, W.P., Rowinsky, E.K., Rosenhein, N.B. et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273–9.

    PubMed  CAS  Google Scholar 

  6. Einzig, A.I., Wiernik, P., Sasloff, J. et al (1990) Phase II study of Taxol in patients with advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol 31, 114

    Google Scholar 

  7. Thigpen, T., Blessing, J., Ball, H. et al (1990) Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a gynecologic oncology group study. Proc. Am. Soc. Clin. Oncol 9604.

    Google Scholar 

  8. Sarosy, G., Kohn, E., Link, C. et al (1992) Taxol dose intensification in patients with recurrent ovarian cancer.Proc. Am. Soc. Cancer. Res. 11, 226.

    Google Scholar 

  9. Lorenz, W., Reichmann, H.J., Schmal, A. et al (1977) Histamine release in dogs by Cremophor EL and its derivatives: oxethy- lated oleic acid is the most effective constituent. Agents and Actions 7, 63–7.

    Article  PubMed  CAS  Google Scholar 

  10. Taxol Investigator s Brochure (1991) National Cancer Institute, Bethesda, MD.

    Google Scholar 

  11. Chabner, B.A. (1991) Taxol. Principles Practice Oncol Updates 5,1–9.

    Google Scholar 

  12. Weiss, R.B., Donehower, R.C., Wiernik, P.H. et al (1990) Hypersensitivity reactions from Taxol. J. Clin. Oncol 8,1263–8.

    PubMed  CAS  Google Scholar 

  13. New, P., Barohn, R., Gales, T. et al (1991) Taxol neuropathy after long term administration. Proc. Am. Assoc. Cancer Res 32,1226.

    Google Scholar 

  14. Rowinsky, E.K., McGuire, W.P., Guarnieri, T. et al (1991) Cardiac disturbances during the administration of Taxol. J. Clin. Oncol 9, 1704–12.

    PubMed  CAS  Google Scholar 

  15. Horwitz, S.B. (1992) Mechanisms of Taxol Resistance Proceedings of the Second National Cancer Institute Workshop on Taxol and Taxus, September 23–24, Alexandria, VA.

    Google Scholar 

  16. Kirschner, L.S., Greenberger, L.M., Hsu, S.I.H. et al (1992) Biochemical and genetic characterization of the multidrug resistance (MDR) phenotype in murine macrophage-like J774.2 cells. Biochem. Pharmacol 43, 77.

    Article  PubMed  CAS  Google Scholar 

  17. Denis, J.N., Greene, A.E., Guénard, D. et al (1988) A highly efficient, practical approach to natural Taxol. J. Am. Chem. Soc. 110, 5917–19.

    Article  CAS  Google Scholar 

  18. Mangatal, L., Adeline, M.I., Guénard, D. et al (1989) Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 45,4177–90.

    Article  CAS  Google Scholar 

  19. Denis, J.N., Correa, A. and Greene, A.E. (1990) An improved synthesis of the Taxol side chain and of RP 56976. J. Organ. Chem. 55,1957–9.

    Article  CAS  Google Scholar 

  20. Kumar, N. (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol Chem 256,10435–41.

    PubMed  CAS  Google Scholar 

  21. Ringel, I. and Horwitz, S.B. (1991) Studies with RP 56976 (Taxotere): a semi-synthetic analog of Taxol. J. Natl Cancer Inst. 83, 288–91.

    Article  PubMed  CAS  Google Scholar 

  22. Guéritte-Voegelein, F., Guénard, D., Lavelle, F. et al (1991) Relationships between the structure of Taxol analogues and their antimitotic activity, J. Med. Chem. 34,992–8.

    Article  PubMed  Google Scholar 

  23. Peyrot, V., Briand, C., Diaz, J.F. and Andreu, J.M. (1992) Biophysical characterization of the assembly of purified tubulin induced by Taxol and Taxotere (RP56976). Proceedings of the Second Interface Clinical and Laboratory Responses to Anticancer drugs: Drugs and Microtubules 24 April, Marseille.

    Google Scholar 

  24. Fromes, Y., Goumon, P., Bissery, M.C. and Fellous, A. (1992) Differential effects of Taxol and Taxotere (RP 56976, NSC 628503) on tau and MAP2 containing microtubules. Proc. Am. Assoc. Cancer Res. 33, 3055.

    Google Scholar 

  25. Riou, J.F., Naudin, A., Lavelle, F. (1992) Effects of Taxotere on murine and human cell lines. Biochem. Biophys. Res. Comm. 187,164–70.

    Article  PubMed  CAS  Google Scholar 

  26. Hanauske, A.R., Degen, D., Hilsenbeck, S.G. et al (1992) Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3,121–4.

    Article  PubMed  CAS  Google Scholar 

  27. Alberts, D.S., Garcia, D., Fanta, P. et al (1992) Comparative cytotoxicities of Taxol and Taxoterein vitro against fresh human ovarian cancers. Proc. Am. Soc. Clin. Oncol 11, 719.

    Google Scholar 

  28. Aapro, M., Braakhuis, B., Dietel, M. et al (1992) Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc. Am. Soc. Clin. Oncol 33, 3086.

    Google Scholar 

  29. Vogel, M.M., Danhauser-Riedl, S., Block, T. et al (1992) Preclinical activity of Taxotere (RP 56976) and Taxol against human tumor colony forming units. Proc. Am. Soc. Clin. Oncol 33, 3115.

    Google Scholar 

  30. Bissery, M.C., Guénard, D., Guéritte- Voegelein, F. and Lavelle, F. (1991) Experimental activity of Taxotere (RP 56976, NSC 628 503), a Taxol analogue. Cancer Res 51,4845–52.

    PubMed  CAS  Google Scholar 

  31. Harrison, S.D., Dykes, D.J., Shepherd, R.V., et al (1992) Response of human tumor xenographs to Taxotere. Proc. Am. Soc. Clin. Oncol 33,3144.

    Google Scholar 

  32. Nicoletti, M.L, Massazza, G., Abbott, B.J. et al (1992) Taxol and Taxotere antitumor activity on human ovarian carcinoma xenografts.Proc. Am. Soc. Clin. Oncol 33,3101.

    Google Scholar 

  33. Bissery, M.C., Vrignaud, P., Bayssas, M. and Lavelle, F. (1992) In vivo evaluation of Taxotere (RP 56976, NSC 628 503) in combination with cisplatinum, doxorubicin, or vincristine. Proc. Am. Assoc. Cancer Res. 33,443.

    Google Scholar 

  34. Rose, W.C. (1992) Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Second National Cancer Institute Workshop on Taxol and Taxus 23–24 September, Alexandria.

    Google Scholar 

  35. Johnson, R.K., Chitnis, M.P., Embrey, W.M. and Gregory, E.B. (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388. Cancer Treat. Rep. 62,1535–47.

    PubMed  CAS  Google Scholar 

  36. Hill, B.T., Whelan, R.D.H., Shellard, S.A., et al (1992) Differential cytotoxic effects of Taxotere in a range of mammalian tumor cell lines in vitro. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy 17–20 March, Amsterdam.

    Google Scholar 

  37. Lowe, M.C. and Davis, R.D. (1987) The current toxicology protocol of the National Cancer Institute. In Principles of Cancer Chemotherapy (eds. S.K. Carter and K. Hellman) McGraw Hill, New York, pp. 228–35.

    Google Scholar 

  38. Extra, J.M., Rousseau, F., Bruno, R. et al (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short I.V. infusion, every 21 days. Cancer Res. 53,1037–42.

    PubMed  CAS  Google Scholar 

  39. Tomiak, E., Piccart, M.J., Kerger, J. et al (1991) A phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous (iv) infusion on a weekly basis. Eur. J. Cancer 27 (Suppl. 2), 1184.

    Google Scholar 

  40. Burris, H., Irvin, R., Kuhn, J. et al (1992) A 43. phase I clinical trial of Taxotere as a 6 hour infusion repeated every 21 days in patients with refractory solid tumors. Proc. Am. Soc. Oncol 11, 369.

    Google Scholar 

  41. Bissett, D., Cassidy, J., Setanolans, A. et al (1992) Phase I study of Taxotere (RP 56976) administered as a 24 hour infusion.Proc. Am.Assoc. Cancer Res. 33, 3145.

    Google Scholar 

  42. Pazdur, R., Newman, R.A., Newman, B.M. et al (1992) Phase I trial of Taxotere: five-day schedule. Cancer Inst 84,1781–8.

    Article  CAS  Google Scholar 

  43. Lefevre, D., Riou, J.F., Zhou, D.et al (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell Une: decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.Biochem. Pharmacol 41, 1967–79.

    Article  PubMed  CAS  Google Scholar 

  44. Piccart, M.J., Gore, M., Ten Bokkel Huinink, W. et al (1993) Taxotere (RP56976, NSC628503): an active new drug for the treatment of advanced ovarian cancer (OVCA). Proc. Am. Soc. Clin. Oncol 12, 258.

    Google Scholar 

Download references

Authors
  1. M. J. Piccart
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynaecology, Northern General Hospital, Sheffield University, Sheffield, UK

    Frank Sharp  & Tony Blackett  & 

  2. The Samaritan Hospital for Women, St Mary’s Hospital Medical School, London, UK

    Peter Mason

  3. Division of Gynecologic Oncology, UCLA School of Medicine, Los Angeles, USA

    Jonathan Berek

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Chapman & Hall

About this chapter

Cite this chapter

Piccart, M.J. (1995). Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-0136-4_22

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-0138-8

  • Online ISBN: 978-1-4757-0136-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation